EV-302: Enfortumab Vedotin and Pembrolizumab
Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the EV-302 study and the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.